Topic: Updates on Diagnosis and Treatment Strategies of MASLD-Related HCC

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a leading cause of liver-related morbidity worldwide, often progressing to hepatocellular carcinoma (HCC). As the prevalence of obesity and metabolic syndrome rises, the association between MASLD and HCC becomes increasingly significant, necessitating a comprehensive understanding of their interplay. This Special Issue aims to illuminate recent advancements in diagnosis and treatment strategies, providing clinicians and researchers with the latest insights into this complex condition.

The issue begins by establishing the epidemiological landscape of MASLD, highlighting its impact on public health and the urgent need for effective intervention strategies. Following this, we delve into the pathophysiological mechanisms that link metabolic dysfunction to liver carcinogenesis, setting a foundation for improved diagnostic approaches. Novel biomarkers and advanced imaging techniques are explored, emphasizing their roles in early detection and surveillance.

Moreover, lifestyle interventions remain a cornerstone of management; thus, discussions on the effectiveness of weight loss and dietary changes are included. We also review pharmacological advancements, particularly in targeted therapies, to provide a comprehensive overview of current treatment options. Additionally, innovative combination therapies and the future research directions necessary for furthering our understanding of MASLD-related HCC are considered.

By compiling expert perspectives and cutting-edge research, this Special Issue seeks to empower healthcare providers in their clinical practice, ultimately enhancing patient outcomes in the context of MASLD and HCC.

Potential topics include, but are not limited to, the following:
1. Pathophysiological Insights into MASLD-Related Carcinogenesis;
2. Novel Biomarkers for Enhanced Diagnostic Accuracy;
3. Advanced Imaging Techniques in Liver Disease;
4. The Role of Lifestyle Modifications in Management;
5. Innovative Combination Therapies for HCC;
6. Surveillance Strategies for High-Risk Populations.

31 Dec 2024